Geron Corp (GERN) Stock Price & Analysis

Geron Corp (GERN) rose 3.97% to USD 1.57 as of September 8, 2026 at 10:59 UTC, according to Nexqual real-time market data.

GERN last closed at USD 1.57; the session ranged USD 1.46–1.59 on volume of 11,478,945 shares. Market capitalization is —, with a 52-week range of USD 1.04–2.01 (NMS). Source: Nexqual, September 8, 2026 at 10:59 UTC.

Key Statistics (as of September 8, 2026 at 10:59 UTC)

Technical Analysis (GERN)

Nexqual's technical model rates GERN "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 10:59 UTC.

From Geron Corp's Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• We believe that the results of our Phase 3 clinical trial, IMerge, in LR-MDS, favorable FDA label and National Comprehensive Cancer Network, or NCCN®, Clinical Practice Guidelines in Oncology, or NCCN Guidelines®, position RYTELO as a potential treatment that can compete for significant market segments in lower-risk MDS, including second-line ESA ineligible patients regardless of prior treatment or RS status and first-line ESA ineligible patients.
• Imetelstat, our proprietary telomerase inhibitor which was discovered and developed at Geron, was designed to inhibit telomerase in malignant cells with continuously upregulated telomerase.

Partnerships

• To enable paid access to patients outside the United States through approved Named Patient Programs (NPPs), we have partnered with Tanner Pharma, a distributor with broad global reach to support patient access.
• In accordance with the termination provisions of the Prior Collaboration Agreement, we have an exclusive worldwide license for intellectual property developed under the Prior Collaboration Agreement for the further development, commercialization and marketing of imetelstat, without any economic obligations to Janssen with respect to such license.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:59 UTC. This page is informational and not investment advice.